) recently revealed that it won clearance from the FDA for its
xTAG Gastrointestinal Pathogen Panel, which is a complete
molecule-based diagnostic assay. It tests for over 90% of
parasitic, bacterial and viral reasons for gastroenteritis in one
assay. The xTAG Gastrointestinal Pathogen Panel has been
commercialized in the U.S. It is believed that its use will
permit better detection of pathogens.
The xTAG Gastrointestinal Pathogen Panel is a complete
multiplexed offering. The assay concurrently tests for as many as
eleven of the most frequently occurring causes of
gastroenteritis. The xTAG Gastrointestinal Pathogen Panel is able
to provide outcomes in less than five hours. The assay is meant
for the Luminex 100/200 system.
Earlier, Luminex accomplished the takeover of U.S.-based
diagnostic testing company, GenturaDx on July 11, 2012. The
GenturaDx deal is in line with Luminex's strategy of pursuing
acquisitions to drive growth. Its technology when combined with
Luminex's MultiCode chemistry will enable the company to develop
user-friendly advanced products for its customers.
Luminex possesses an extensive product portfolio and a strong
pipeline of novel assays, which are expected to support growth
going ahead. The company is awaiting FDA approval for its
NeoPlex4 assays to drive future growth. It may benefit from its
latest acquisitions if it maintains integration synergies.
However, Luminex operates in a highly competitive life
sciences industry. The company competes with
Life Technologies Corporation
), among others. Moreover, sluggish growth in its core markets as
well as the ongoing European austerity measures are challenges
faced by Luminex. We are currently Neutral on the stock, which
carries a short-term rating of Zacks Rank #3 (Hold).
AFFYMETRIX INC (AFFX): Free Stock Analysis
LIFE TECHNOLOGS (LIFE): Free Stock Analysis
LUMINEX CORP (LMNX): Free Stock Analysis
SEQUENOM INC (SQNM): Free Stock Analysis
To read this article on Zacks.com click here.